T cell receptor beta variable 7-2 (TRBV7-2)

T cell receptor beta variable 7-2 (TRBV7-2) is a protein coding gene encoding the variable domain of the T cell receptor (TCR) β chain[1]. The TCR is a heterodimeric cell-surface receptor, consisting of α and β chains, that is essential for the adaptive immune response through recognition of antigenic peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[2]. The variable region (Vβ), including TRBV7-2, confers specificity to individual T cells by forming the antigen-binding site in combination with the TCR α chain, enabling recognition of a vast array of antigens. Signaling through the TCR complex upon antigen recognition initiates a cascade involving CD3 and tyrosine kinases, leading to T cell activation, proliferation, and effector function[1][2]. TRBV7-2 is one of the many variable segments generated by somatic V(D)J recombination during T cell development, contributing to the diversity of the immune repertoire[2]. Aberrant or clonally expanded Vβ regions, including TRBV7-2, can be involved in autoimmunity (such as rheumatoid arthritis) and may serve as biomarkers of T cell clonality in disease or immune monitoring[4]. Though there are currently no drugs that specifically target TRBV7-2, therapies that modulate T cell receptor signaling can interact with T cells expressing this segment, and safety concerns include excessive immune activation and potential for autoimmunity[2][4].

Other names

TRBV7-2TRBV72TCRBV6S5A1N1TCRBV7S2T-cell receptor beta chain V regionV_segment translation product

Drugs targeting the T cell receptor complex typically act by modulating T cell activation, cytokine release, or inducing cell death (e.g. anti-CD3 triggers TCR-CD3 complex signaling, leading to T cell depletion or modulation). CAR-T therapy involves genetic engineering of TCR or CAR specificity in T cells (for which Vβ segments may affect specificity).